475830.KQ ORUM

Healthcare Biotechnology KOSDAQ
15,320 KRW
Close of Oct 31, 2026
14,990 146,600
Market cap
KRW 333B
P/E
18.6x
P/B
1.79x
ROE
51.7%
Dividend yield
-
Fundamental score
1.4/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 475830.KQ undervalued?

Graham number
Price15,320
Graham value12,615
Premium21.4%

475830.KQ trades 21.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ORUM fundamental analysis

7 of 22 checks passed

ROE 2/2

High return on equity (51.7%), above 20%.

ROA 1/1

Return on assets (33.0%) is above the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-620.7%) is below the industry median (4.8%).

Revenue Growth 0/2

Revenue shrank 32.3% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 51.6x against interest expense, well covered.

PE vs Market 0/1

PE (18.6x) is above the market median (11.3x).

PE vs Industry 1/1

PE (18.6x) is below the industry median (28.9x).

PBV 1/1

Price to book (1.8x) is below the industry median (2.4x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 33.2, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

ORUM stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ORUM

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies; and ORM-1023, which is in pre-clinical tr…

Full company profile